Baseline characteristics of cohort (n=3039)
| Characteristic | Value* | |
|---|---|---|
| Age (years, mean±SD, median) | 65±12, 65 | |
| Gender (n, %) | ||
| Male | 2966 | 97.6% |
| Ethnicity (n, %) | ||
| African-American | 414 | 13.6% |
| Caucasian | 670 | 22.0% |
| Hispanic | 44 | 1.45% |
| Other | 341 | 11.2% |
| Not documented | 1570 | 51.7% |
| Baseline serum creatinine (mg/dL, mean±SD, median) | Mean±SD, Median | |
| Overall (n=3039) | Overall: Overall: 1.28±0.86, 1.10 | |
| Group 1: <1.5 mg/dL (n=2497) | Group 1: <1.5 mg/dL=1.05±0.19, 1.03 | |
| Group 2: 1.5–2.0 mg/dL (n=377) | Group 2:1.5–2.0 mg/dL=1.67±0.16, 1.6 | |
| Group 3: >2 mg/dL (n=165) | Group 3: >2 mg/dL=3.75±2.44, 2.7 | |
| n | Per cent | |
| Comorbidities | ||
| Diabetes mellitus | 866 | 28.5 |
| Hypertension | 1343 | 44.2 |
| Chronic heart failure | 177 | 5.8 |
| Coronary artery disease | 445 | 14.6 |
| Gout | 69 | 2.3 |
| SBP <100 mm Hg | 88 | 2.9 |
| Concomitant use of: | ||
| NSAIDs | 1053 | 34.6 |
| Diuretics (total) | 1771 | 58.3 |
| Loops | 773 | 25.4 |
| Thiazides | 1264 | 41.6 |
| K-sparing | 239 | 7.9 |
| β-blockers | 1601 | 52.7 |
*Values are reported as mean±SD; median unless otherwise noted.
NSAIDs, non-steroidal anti-inflammatory drugs; SBH, systolic blood pressure.